Cell Therapy News

Crystal L. Mackall, MD, will receive Sarcoma Foundation of America’s Nobility in Science Award.

Prolonged responses to chimeric antigen receptor T-cell therapy for advanced multiple myeloma may depend on the composition of the patient’s post-treatment immune microenvironment, results from a retrospective study showed.

The FDA approval of the first ever chimeric antigen receptor T-cell therapy for multiple myeloma in 2021 laid the groundwork for others to follow.

Unequal distribution of trial sites nationwide has led to inequitable access to cutting-edge immunotherapies among Black patients with advanced multiple myeloma, according to research published in JAMA Network Open.

Researchers who identified proteins that influence T-cell formation have leveraged their discovery to develop a process that boosts the efficacy of chimeric antigen receptor T-cell therapy for solid tumors.

The FDA approved betibeglogene autotemcel for treatment of patients with beta-thalassemia who require routine red blood cell transfusions.

Idecabtagene vicleucel extended PFS compared with standard regimens for adults with advanced multiple myeloma, according to topline data released by the agent’s manufacturer.

Younger patients who received higher doses of tisagenlecleucel for advanced B-cell acute lymphoblastic leukemia achieved better outcomes, according to results of a retrospective study.

Owhofasa Agbedia, MD, MPH, received this year’s ASH-CIBMTR-ASTCT Career Development Award.

The FDA lifted its clinical hold on a trial designed to evaluate CYAD-101, an investigational chimeric antigen receptor T-cell therapy.